Translating Complex Biology into Breakthrough Medicines
Most drug discovery starts from the molecule and its target. We start from the cell: we identify the response a drug must trigger there, its cellular mechanism of action, and let that biology drive the chemistry.
Many drugs reach clinical trials with the wrong mechanism, so they fail on efficacy or safety.
90% of clinical candidates fail. Chemistry can now be optimized fast, but the drug's biology is still poorly understood: the mechanism is set early, by precedent or trial and error, and validated only in the clinic, years later.
We bring AI to cell signaling, the layer where a drug's outcome is decided.
AI works where data is clean: genomics to find targets, chemistry and structure to design molecules. Conventional discovery has the same focus, the binding of the molecule to its target. Both stop short of what happens next, the cell signaling that decides the outcome, or oversimplify it to a few readouts at a single time point.
InterAx Deep Signal™ measures the cell's response over time, in living cells. Its mathematical model of the whole system turns each experiment into mechanistic parameters for each pathway and for the cross-talk between them: a dataset AI can learn from, and the design objective for the chemistry, already in discovery.
Before clinical trials, we get the mechanism right: biology drives the chemistry.
Deep Signal is built into the design cycle. First it determines the right cellular profile for efficacy and tolerability, then each design round aims the chemistry at it.
- Time-resolved, multi-pathway signaling assays in living cells.
- A mechanistic model turns each readout into the compound's cellular profile and links it to clinical outcome.
- GPCR molecular dynamics, quantum chemistry and ultra-large virtual screens.
- Generative AI design, machine-learning property prediction and medicinal chemistry, with synthesis at contract research organizations.
Our programs, designed from the cellular mechanism up.
GLP-1
Oral small molecule for obesity and type 2 diabetes, built on the cellular profile that gives the injectable peptides their efficacy and tolerability, a profile no oral compound reported so far has matched. Preclinical with in vivo data. IND targeted for Q4 2027.
Metabolic program
Oral small molecule for obesity, undisclosed target. Preclinical.
New therapeutic areas
CNS (undisclosed indication), inflammation and autoimmune disorders.
Backed by partners, grants and investors.
For every dollar of equity raised, InterAx has secured half a dollar of non-dilutive funding.
Discuss an asset or a co-development.
More drugs should enter Phase 2 with the right mechanism. We partner differentiated GPCR candidates with pharma and biotech. If you want a candidate in a GPCR indication where the current drugs fall short on efficacy or tolerability, or are building a company around a disease area, we would like to talk.